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Background: Desmoplastic small round cell tumour (DSRCT) is a rare but frequently fatal sarcoma, and many of its
characteristics still require further clarification.
Methods: We retrospectively analysed 41 patients treated at or referred to two regional referral centres in the UK
between 1991 and 2012. A review of the current literature was also performed.
Results: The median age of presentation was 27 years (range 16 to 45 years), with a male-to-female ratio of 3:1.
Ninety percent of patients had disease in the abdomen. The median size of the presenting tumour was 13 cm
(range 3.5 to 23 cm), and 80% had metastatic disease at diagnosis, mainly in the liver (33%) and lungs (21%).
Time-to-progression (TTP) was 3.9, 2.3 and 1.1 months after first-, second- and third-line chemotherapy, respectively.
First-line treatment with VIDE chemotherapy appeared to confer the longest TTP (median 14.6 months). Ifosfamide
and doxorubicin resulted in TTP of >3.8 months when used in any-line setting. Eleven patients received targeted
agents as part of a clinical trial. After a median follow-up of 14 months, the overall median survival (MS) was
16 months. There was no difference in MS with regards to age, gender, or size of the presenting tumour. Patients
with extra-abdominal disease survived longer compared to those with tumours in the abdomen (all still alive vs MS of
15 months; P = 0.0246). Patients with non-metastatic intra-abdominal disease who underwent surgery had an MS of
47 months (16 months for those who did not have surgery; P = 0.0235). Radiotherapy for locoregional control in
patients with metastatic intra-abdominal DSRCT was associated with longer survival (MS of 47 vs 14 months; P = 0.0147).
Conclusions: DSRCT is a rare but often fatal disease that mainly affects younger male patients. Those with
intra-abdominal DSRCT have a poorer prognosis, although surgical resection for localised disease and radiotherapy in
the metastatic setting are associated with improved survival. A patient’s age, gender and size of presenting tumour do
not have prognostic significance.
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Desmoplastic small round cell tumour (DSRCT) is a rare
but highly aggressive neoplasm that typically occurs in
adolescent and young males. An earlier study has found
a male-to-female ratio of approximately 5 to 1 and a
mean age at diagnosis of 22 years [1]. First described
in 1989, it is characterised by clusters of poorly* Correspondence: han.wong@addenbrookes.nhs.uk
1Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation
Trust, Hills Road, Cambridge CB2 0QQ, UK
Full list of author information is available at the end of the article
© 2013 Wong et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.differentiated small round blue cells lying within an
abundant fibrosclerotic stroma [2]. These cells co-express
epithelial, mesenchymal, myogenic and neural markers [3],
but are distinguished by the chromosomal translocation
t(11;22)(p13;q12) resulting in the fusion of the Ewing’s
sarcoma (EWSR1) and the Wilms’ tumour (WT1) genes
[4]. DSRCT generally develops in the abdomen and have
a tendency towards peritoneal spread, with subsequent
metastasis to distant lymph nodes, liver and lungs [5].
In this study, we retrospectively reviewed 41 patients
with DSRCT who were treated at or referred to twotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient characteristics (n = 41)




Median age (years) 27 (range 16 – 45)
Presenting site





Median tumour size at diagnosis (cm) 13 (range 3.5 – 23)
Metastasis at presentation 33 (80%)
Sites of metastasis at presentation (n = 33)
Liver 11 (33%)
Lung 7 (21%)
Peritoneal cavity 6 (18%)
Lymph node 5 (15%)
Bone 3 (9%)
Adrenal 1 (3%)
Chest wall 1 (3%)
Prostate 1 (3%)
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and prognostic factors, as well as review of the current
literature on the management of DSCRT, was performed.




The Royal Marsden Hospital in London and in Sutton,
UK, and Addenbrooke’s Hospital in Cambridge, UK,
are regional sarcoma referral centres for London and
South East England, and for East of England, respectively.
Patients with DSRCT treated at or referred to these
two centres between the years of 1991 and 2012 were
identified retrospectively. Diagnosis was confirmed by
immunohistochemistry and reviewed by central specialist
histopathologists. Cytogenetic analysis for EWSR1-WT1
rearrangement was performed when available. Patients’
medical and treatment records were analysed. All 41
patients identified were included in the study. Approval
from the local research ethics committee was obtained
prior to data collection.
Statistical analysis
Time-to-progression (TTP) is the time interval from
completion of chemotherapy to radiological disease pro-
gression as defined by Response Evaluation Criteria in
Solid Tumours (RECIST). Survival analysis was performed
using the Kaplan-Meier method and log rank test. Surviving
patients were censored at last contact.
Results
Patient characteristics
A total of 41 patients were referred to or treated at
the centres between 1991 and 2012. Thirteen of these
were referred for opinion only and were managed sub-
sequently at their local hospitals. Diagnosis of DSRCT
was confirmed by central specialist histopathological
review. Cytogenetic testing for EWSR1-WT1 rearrange-
ment was only routinely available in some centres after
2008, therefore only 14 patients were tested and found
to be positive. Patient characteristics are summarised in
Table 1. The age of presentation ranges from 16 to
45 years, with a median of 27 years. About three quarter
of the patients were males. The majority of patients
presented with abdominal or pelvic tumours (i.e. arising
from the retroperitoneum or within the peritoneal cavity
with no clear indication of organ of origin), with sizes
ranging from 3.5 to 23 cm. Four patients with extra-
abdominal disease had disease in the prostate, testis,
shoulder and thigh, respectively. Eighty percent of the
patients had evidence of metastasis at presentation,
with lungs and liver being the commonest sites.Treatments
The treatments received by this cohort of patients are
summarised in Table 2. Thirty eight patients (93%) have
had chemotherapy, with the majority of them receiving
it with palliative intent. Four and two patients received
neoadjuvant and adjuvant chemotherapy, respectively. Of
these, three subsequently developed metastatic disease.
The commonest chemotherapeutic regimes were those
frequently used in other small round cell tumours, i.e. a
combination of an anthracycline, alkylating agent and
vinca alkaloid. Topoisomerase inhibitors, taxanes and
platinums have also been used. As the effectiveness of
second- or subsequent-line chemotherapy is also unproven,
a number of newer agents had been given as part of a
clinical trial, including inhibitor of the mammalian target
of rapamycin (mTOR) pathway, tyrosine kinase inhibitors
(TKIs), and antibody against the insulin-like growth
factor-1 receptor (IGF-1R).
In our series, only six patients received radiotherapy.
One patient each had radical radiotherapy after resection
of an abdominal (54 Gy in 30 fractions) and thigh (60 Gy
in 30 fractions) tumour, respectively. The remaining four
patients received palliative conformal radiotherapy (20 Gy
in five fractions) to the abdomen for locoregional control
in metastatic disease. Resection or optimal debulking of
the primary tumour was done in eight patients, whereas






- Neoadjuvant 4 (10%)
- Adjuvant 2 (5%)




- Radical 2 (5%)
- Palliative 4 (10%)
Surgery and its indications
- Diagnosis 14 (34%)





- Vincristine + ifosfamide +
doxorubicin + etoposide (VIDE)
13
- Ifosfamide + vincristine + actinomycin
D + doxorubicin (IVADo)
7
- Cyclophosphamide or ifosfamide + etoposide 4
- Vincristine + doxorubicin +
cyclophosphamide (VAC) or vincristine +
ifosfamide + doxorubicin
4
- Bleomycin + etoposide + cisplatin 2
- Ifosfamide + doxorubicin 2
- Carboplatin + etoposide 1
- Carboplatin + paclitaxel 1




- Epirubicin + cisplatin + capecitabine 1
- Ifosfamide + carboplatin + etoposide 1
- Ifosfamide + vincristine + actinomycin D 1
Subsequent-line (with chemotherapeutic agents)
- Platinum + etoposide 10
- Etoposide 5
- Ifosfamide + etoposide 5
- Doxorubicin 2
- Ifosfamide + doxorubicin 2
- Cyclophosphamide + topotecan 2
- VAC 2
- Gemcitabine or irinotecan + temozolomide 2
- Albumin-bound paclitaxel 1
- Cisplatin + mitomycin C + irinotecan 1
- Doxorubicin + etoposide 1
Table 2 Treatment and chemotherapeutic regimens
(n = 41) (Continued)
- IVADo 1
- Liposomal doxorubicin 1
- VIDE 1
Subsequent-line (with non-standard therapies)
- Figitumumab 2
- Sirolimus + cyclophosphamide or
liposomal doxorubicin
2
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purposes.Time-to-progression and survival
TTP after first- to third- line systemic therapies are
summarised in Table 3. Unsurprisingly, the median TTP
decreases with increasing lines of treatment. First-line
treatment with VIDE chemotherapy appeared to confer
the longest TTP (median of 14.6 months; range 1.9 to
33.7 months). In second-line treatment, etoposide alone
(n = 1), or in combination with platinum (n = 9) or ifosfa-
mide (n =2), were most commonly used, with a median
TTP of 3.4 months (range 0.3 to 13.9 months). Ifosfamide
and doxorubicin treatment resulted in a median TTP
of >3.8 months when used in any line-setting.
The median follow-up period for all patients was
14 months (range 1 to 127 months). Sixteen (39%) patients
were still alive at a median follow-up of 12.5 months. All
deaths were due to the disease. The overall median survival
(MS) was 16 months (range 2 to >127 months) (Figure 1).
Three-year and 5-year survival rates were 27% and
16%, respectively. The longest surviving patient had
disease in his prostate, and he presented early with
symptoms of urinary outflow obstruction. He still has
no evidence of disease for more than 10 years after his
initial diagnosis. Three other patients who presented
early with lumps in the testis, shoulder and thigh,Table 3 Time-to-progression after systemic therapy
Line of treatment Median time-to-progression (months)
First (n = 38) 3.9 (range 0.6 to 33.7)
Second (n = 23) 2.3 (range 0.3 to 13.9)
Third (n = 13) 1.1 (range 0.6 to 11.8)
Figure 1 Kaplan-Meier plot of overall survival for the entire
cohort (n = 41).
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albeit with evidence of metastatic disease.
There was no difference in MS with regards to age
(15 vs 16 months for those ≤25 years and >25 years,
respectively; P = 0.7899), gender (16 vs 15 months for
males and females, respectively; P = 0.5369), or whether
the presenting tumour was ≤ or >10 cm (32 vs 13 months;
P = 0.4195) (Figure 2).
Patients with extra-abdominal disease (n = 4) survived
longer compared to those with tumours in the abdomen
or pelvis (n = 37) (all still alive vs MS of 15 months,
respectively; P = 0.0246). Patients with non-metastatic,
intra-abdominal and -pelvic disease at presentation who
had undergone surgical resection of the primary tumour
(n = 6) survived much longer than those who did not
have surgery (n = 11) (MS of 47 vs 16 months, respectively;
P = 0.0235). The decision on surgery depended largely
on the site of disease and resectability. Four patients
who underwent resection had received either neoadjuvant
(n = 2) and adjuvant (n = 2) chemotherapy, one of
whom remains disease-free 10 years after his curative
surgery.
Four patients with metastatic, intra-abdominal DSRCT
had radiotherapy for locoregional control – when com-
pared to a similar group of patients who did not receive
radiotherapy (n = 29), a significant difference in MS
was noted (47 vs 14 months, respectively; P = 0.0147)
(Figure 3).Discussion and review of the literature
In this report, we present one of the largest series of
patients with DSRCT. Consistent with previously pub-
lished data, DSRCT tends to occur in younger males.
Most patients presented with abdominal or pelvic tumours
and many have evidence of metastases, the majority being
in the lungs and liver.Multimodality treatment of DSRCT and prognostic factors
The reported MS of DSRCT is in the region of 17 to
25 months [6]. Given the poor outcome of the disease
and the significant morbidities and mortality associ-
ated with its treatment, prognostic indicators are very
important. Two retrospective studies performed at the
Memorial Sloan-Kettering Cancer Center (MSKCC) have
both found that aggressive surgical debulking of DSRCT is
of prognostic significance [7,8]. An analysis of 32 patients
by Schwarz et al. demonstrated that improved survival
was found to be associated with the following: more
than 90% surgical debulking either before or after
chemotherapy, complete or very good partial response
(PR) to multimodality treatment, and use of the P6
protocol (see below) [7]. In a report of 66 patients by
Lal et al., treatment with chemotherapy, surgery and
radiotherapy conferred a 3-year survival of 55% com-
pared to 27% for those who did not receive all three
treatments [8]. In addition, gross tumour resection was
also associated with prolonged survival (3-year survival
of 58% compared to 0% in the non-resected patients).
Naturally such an analysis performed retrospectively
cannot adequately control for the fact that patients
with radically resectable disease are likely to have less
bulky and more localised tumours.
There is no general consensus on the best therapeutic
approach, as strong evidence is lacking given the rarity
of the disease, although multimodality treatment with
chemotherapy, surgery and radiotherapy appears to
represent optimal management. The MS of patients
diagnosed with DSRCT was 16 months in this study,
which is slightly lower than those reported previously
[6]. Comparatively, it is clear that the management in
our centres took a more conservative approach than
others, as evident by the less frequent use of radiotherapy,
surgery and myeloablative chemotherapy with stem cell
transplantation. In a review by Hassan et al. of 12 patients
with intra-abdominal DSRCT (all of whom had received
multi-agent chemotherapy), those who underwent surgical
resection had a longer MS of 34 months compared to
14 months for those who had biopsy alone [9]. In our
study, the MS observed for patients who had resection
for their abdominal or pelvic tumours was 47 months,
compared to 16 months for those who did not. Moreover,
for patients with metastatic intra-abdominal DSRCT,
palliative radiotherapy for locoregional disease control
appeared to confer a survival advantage (MS of 47 vs
14 months in those who did not have radiotherapy).
Although patients with localised abdominal or pelvic
disease who underwent surgery appear to have similar
MS (i.e. 47 months) compared to those with metastatic
disease who received palliative radiotherapy, they are
by no means comparable and surgery is still indicated
in resectable DSRCT. In our series, the only patient
Figure 2 Factors not associated with prognostic significance. Kaplan-Meier plots of overall survival stratified according to patient’s (a) age,
(b) gender and (c) size of the primary tumour.
Figure 3 Factors associated with prognostic significance. Kaplan-Meier plots of overall survival stratified according to (a) site of disease
(abdomen/pelvis (n = 37) or other sites (n = 4)), (b) whether patients had undergone surgical resection (n = 6) or not (n = 11) for localised
intra-abdominal disease and (c) whether patients with intra-abdominal metastatic disease had radiotherapy (n = 4) or not (n = 29) for
locoregional control.
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10 years from diagnosis) has had chemotherapy and
surgical resection. Hence, a more aggressive multimod-
ality treatment approach would seem to be indicated in
order to prolong survival, although larger prospective trials
with quality-of-life measures would be necessary to confirm
this. This is difficult to perform in such a rare disease.
Subbiah et al. presented the largest series of patients
diagnosed with DSRCT at the 2012 American Society of
Clinical Oncology meeting [10]. This was a retrospective
review of 197 patients treated at the MD Anderson Cancer
Center (MDACC) and MSKCC. In that series, 87% were
males with a mean age of presentation of 25 years. In
total, 139 (71%) patients underwent surgery, 38 (19%)
had debulking surgery, 30 (15%) received radiotherapy, 27
(14%) had intraperitoneal chemotherapy after debulking,
and 11 (5%) had stem cell transplant. They found that
radiotherapy, surgery, intraperitoneal chemotherapy, re-
moval of primary mass and metastases, age <30 years and
patients treated after 2003 were associated with improved
survival. In contrast, our study did not show a difference
in survival with regards to age of presentation. We also
found that the patient’s gender and size of the presenting
tumours do not have an impact on survival. Although
uncommon, patients who did not have disease in the
abdomen appeared to have a better outcome. This is likely
to be related to earlier presentation, less advanced disease
and in some cases the feasibility of radical resection.
Chemotherapy
DSRCT is sensitive to chemotherapy although a transient
response followed by disease progression is the norm.
Chemotherapeutic regimes used are normally similar to
those for treating Ewing’s sarcoma. Farhat et al. treated
five patients with a chemotherapeutic regime consisted
of cisplatin, etoposide, cyclophosphamide and an anthra-
cycline – disease stabilisation lasting 4 to 9 months were
noted in four patients with intra-abdominal DSRCT
after initial surgery, whereas one patient with relapsed
metastatic disease from an initial paratesticular primary
attained a complete response (CR) [11]. The authors also
reviewed the literature of 60 patients who were treated by
chemotherapy with or without abdominal radiotherapy,
and objective responses were found in 17 patients,
eight of whom achieved a CR. The chemotherapy
agents associated with CR were those of doxorubicin,
cyclophosphamide, vincristine and cisplatin. These are
in line with our results, with these drugs providing the
longest TTP. Chemotherapy is often given in the metastatic
setting; and although often used, the role of neoadjuvant
and adjuvant chemotherapy in localised disease remains
unknown.
Kushner et al. reported 12 patients (10 treatment-naïve
and two had previous chemotherapy) who received theP6 protocol, which has seven courses of chemotherapy
consisting of cyclophosphamide, doxorubicin, vincristine
(HD-CAV), etoposide and ifosfamide [12]. This was
followed by surgery, radiotherapy, and myeloablative
chemotherapy using thiotepa and carboplatin with stem
cell rescue in some cases. All tumours showed a PR with
this regimen although there was no CR, and survival of
around 20 months was reported. This protocol is used
in many centres, mainly in resectable cases, although
treatment-related toxicities could be severe. Whether
the intensive P6 regimen is better than standard first-line
chemotherapy regimens used in other small round blue
cell tumours, such as Ewing’s sarcoma, is unknown. In
two prospective studies by Bertuzzi et al., a total of 17
patients were treated with induction chemotherapy
consisting of ifosfamide, epirubicin and vincristine –
those who responded were then treated with high-dose
chemotherapy and stem cell rescue in conjunction with
local therapy (surgery and/or radiotherapy) [13,14].
Approximately half of them achieved an initial PR to
induction chemotherapy, but no CR was achieved with
high-dose chemotherapy. The MS reported was 14 months,
leading the authors to question the role of high-dose
chemotherapy in the treatment of DSRCT. More recently
in a retrospective study using data obtained from the
Center for International Blood and Marrow Transplant
Research, Cook et al. reported the outcome of 36 DSRCT
patients who had undergone autologous stem cell
transplantation [15]. The benefit was much greater for
those who achieved a CR pre-transplantation compared
to those who did not, with MS of 36 and 21 months,
respectively.
The use of other chemotherapy drugs has been reported,
including irinotecan, temozolomide and vinorelbine,
but none of them showed superiority [16,17]. Evidence
and experience is emerging on the role of trabectedin
in the management of metastatic DSRCT [18-20]. In a
case report, an 18-year-old boy with abdominal DSRCT
was initially treated by complete surgical excision, followed
by adjuvant chemotherapy with cyclophosphamide, do-
xorubicin/actinomycin D, vincristine, alternating with
ifosfamide and etoposide [20]. Disease recurrence was
treated with surgery and cisplatin and irinotecan, but this
was followed by further progression for which trabectedin
was given, resulting in PR. This resulted in a survival of
4 years from diagnosis.
Similar to ovarian cancer, the use of hyperthermic
intraperitoneal chemotherapy has also been reported
given the tendency of the disease to spread within the
peritoneum. Heated cisplatin is given at a dose 100 to
150 mg/m2 intraperitoneally after optimal cytoreductive
surgery. The series reported by the MDACC showed
that this method is safe and might have activity in
paediatric patients, and a survival benefit has also been
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this could be widely adopted.Radiotherapy
Whole-abdominopelvic radiotherapy (WAP-RT) after max-
imal surgery was first reported by Kushner et al. at the
MSKCC as part of a multimodality treatment using the
P6 protocol, with the aim of improving local control
[12]. A total dose of 30 Gy was delivered post-operatively,
with simultaneous boost given to sites of gross residual
disease. Conventional two-dimensional radiotherapy was
associated with significant gastrointestinal and haemato-
logic toxicities, with long term side effects including
small bowel obstruction and ureteral stenosis [24]. For
this reason, the use of WAP intensity-modulated radiation
therapy (WAP-IMRT) was studied by Pinnix et al. at
the MDACC [25]. All of the eight patients had received
prior chemotherapy and surgical debulking (seven of
them also had intraperitoneal cisplatin). One patient was
still disease-free 20 months after treatment, although
the rest experienced either local or distant failure after
a median of 8.73 months fromWAP-IMRT. A retrospective
analysis at the MSKCC looked at 31 patients who under-
went WAP-RT, either with conventional two-dimensional
radiotherapy (n = 22) or IMRT (n = 9) after chemotherapy
and maximal debulking surgery [26]. IMRT was associated
with lower incidence of acute gastrointestinal and
haematologic toxicities. The 3-year overall survival and
progression-free survival (PFS) rates were 50% and 24%,
respectively. Anecdotally, a patient in this series who
received WAP-RT developed a serious malabsorption
syndrome subsequent to gastrointestinal damage. Given
the limited data of efficacy, WAP-RT is currently not
routinely used in the management of DSRCT.Targeted therapies
In recent years, targeted therapies have been studied in
DSRCT. Drugs that have shown activity against this
disease include the TKI sunitinib and the mTOR in-
hibitor temsirolimus [27,28]. In our cohort of patients,
other non-standard agents used include the anti-IGF-1R
antibody figitumumab, the TKIs axitinib, pazopanib,
sorafenib and sunitinib, as well as the mTOR inhibitor
sirolimus. The number of patients is too small to draw
any conclusion about their efficacy. Due to the fact
that DSRCT has a predilection to occur in young
males, Fine et al. discovered that androgen receptor is
expressed in 37% of DSRCT [29]. Six of their patients
were treated with combined androgen blockade and
three attained a clinical benefit. In our study, one patient
had received the gonadotropin-releasing hormone agonist
goserelin. However, no significant anti-tumoural efficacy
was noted.Chromosomal translocation resulting in the fusion of
the EWSR1 and WT1 genes is the molecular characteristic
of DSRCT. The resulting fusion protein has been found to
activate the IGF-1R gene promoter, causing the expression
of this anti-apoptotic receptor tyrosine kinase [30-32]. The
understanding of this mechanism has provided a novel
target for the treatment of this disease. In a recent phase
II study, 16 patients with DSRCT who had had previous
treatments were given 12 mg/kg of the anti-IGF-1R anti-
body ganitumab intravenously [33]. Common side effects
include fatigue, nausea, dyspnoea and peripheral oedema.
PR was noted in one (6%) patient, whereas 10 (63%)
had stable disease (SD) as their best response, with 3
(18%) achieving SD lasting ≥24 weeks. Median PFS was
19 months, indicating a potential role of ganitumab
used either alone or in combination with chemotherapy
for patients with DSRCT. In a phase I study of another
anti-IGF-1R antibody cixutumumab in combination
with temsirolimus, two out of three patients with
previously-treated DSRCT had SD lasting longer than
5 months [34].
Tumour-specific antigens have also been studied as
targets for immunotherapy, including the disialoganglio-
side GD2 and the antigen recognised by the antibody
8H9 (expressed in 70% and 96% of DSRCT, respectively)
[35]. In particular, studies of anti-GD2 antibodies have
shown some promising results in the treatment of
neuroblastoma [36]. Another potential therapeutic target
is the lysine-specific demethylase 1, a key histone modifi-
cation enzyme involved in controlling gene expression
which if dysregulated, could result in tumourigenesis
[37]. It is found to be highly expressed in several highly
malignant sarcomas including DSRCT [38]. It could
be inhibited by small molecule inhibitors and further
investigation is warranted.
Conclusions
Advanced DSRCT is a rare, aggressive disease with
invariably poor outcome that generally occurs in young
men. It has a propensity to metastasise and at present,
surgery, combination cytotoxic chemotherapy and radio-
therapy remain the only standard therapeutic options. In
our study, we found that patients with intra-abdominal
DSRCT have a poorer prognosis, although surgical
resection for localised disease and radiotherapy, even
in the metastatic setting for locoregional control, are
associated with improved survival.
Clearly more efforts are needed to improve the progno-
sis of patients with DSRCT, and the development of novel
targeted agents is likely to have a major role in altering the
course of the disease. It is also hope that the International
Rare Cancers Initiative, a multinational collaboration with
the aim of developing clinical trials for uncommon malig-
nancies, will help to address this issue in the future.
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